Liver Diseases  >>  pradigastat (LCQ908)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pradigastat (LCQ908) / Novartis
NCT01387958: A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Terminated
2
32
RoW
LCQ908, Placebo
Novartis Pharmaceuticals
Hepatitis C
02/12
02/12
NCT01811472: Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

Completed
2
52
US
LCQ908, pradigastat, placebo
Novartis Pharmaceuticals
Non-alcoholic Fatty Liver Disease (NAFLD)
09/14
09/14

Download Options